查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2058146

轉移性去勢抗性前列腺癌（mCRPC）：新型療法、未滿足的需求和TPP洞察報告，2026年

Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 德國轉移性去勢抵抗性前列腺癌 (mCRPC) 市場預計將從 2025 年的 3.42 億美元成長到 2035 年的 5.38 億美元，這反映了在新型腫瘤治療方法不斷引入的推動下，市場穩步成長。
  • 市場擴張受以下因素支撐：
  • 新一代雄性激素受體抑制劑和放射性藥物的廣泛應用
  • 擴大聯合療法和序貫療法的應用
  • 雖然患者數量的成長相對緩慢（年複合成長率為 0.5%），但高附加價值治療方法和更長的治療週期正在推動市場成長。
  • 未來的成長取決於精準醫療方法和新型治療方法的整合是否成功，從而提高存活率並延緩抗藥性的產生。

轉移性去勢抗性前列腺癌 (mCRPC) 的新型治療方法和 TPP 見解

Thelansis 發布的「轉移性去勢抗性前列腺癌 (mCRPC)：新型療法、未滿足的需求和 TPP 洞察報告，2026」全面分析了該適應症的關鍵新興治療方法和重大藥物發現機會，包括不斷變化的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解。

轉移性去勢抗性前列腺癌（mCRPC）概述

轉移性去勢抗性前列腺癌（mCRPC）是一種高度進行性的前列腺癌，其特徵是儘管透過雄性激素剝奪療法將睪固酮水平降低至去勢水平，疾病仍會繼續進展。這種情況是由持續的雄性激素受體訊號傳導和替代抗藥性機制引起的，這些機制使得腫瘤能夠持續生長和轉移。

臨床上，轉​​移性去勢抵抗性攝護腺癌（mCRPC）主要轉移至骨骼和淋巴結，引起骨痛、骨折、脊髓壓迫等嚴重併發症，以及疲勞和功能障礙等全身性症狀。這些症狀嚴重影響患者的生活品質，並導致較高的發病率。

目前的治療方案多種多樣，包括新一代雄性激素受體路徑抑制劑、化療、放射性藥物和支持性治療。雖然這些治療方法提高了患者的整體存活率，但大多數患者仍不可避免地會出現治療抗藥性和疾病進展，凸顯了現有治療方案的限制。因此，轉移性去勢抵抗性前列腺癌（mCRPC）仍然是腫瘤學領域創新研究的重點，標靶治療、免疫療法、放射性配體療法和聯合治療的研發旨在延長緩解持續時間並實現個體化治療。

主要亮點

  • 在義大利，預計到 2025 年，轉移性去勢抗性前列腺癌 (mCRPC) 患者人數將增加到 2035 年的 37,500 人，增幅為 0.5%（年複合成長率），這主要受人口老化和生存時間延長的影響。
  • 疾病進展和治療抗藥性仍然是重大挑戰，大多數患者最終都會用盡所有可用的治療方案。
  • 隨著人們對精準腫瘤學、放射性配體療法和聯合療法策略的關注度不斷提高，未來的治療模式預計將發生顯著變化。

基於對醫生和關鍵意見領袖（KOL）的調查得出的結論：

  • 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更深入的見解，從而進一步豐富了研究成果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興治療方法的患者
  • 大公司
  • 主要作用機制
  • 發布日期等的預測
  • 臨床試驗趨勢分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等。
  • 未滿足的需求和機遇
  • 目前主要治療方法的有效性
  • 未滿足需求的關鍵領域
  • 估算主要未滿足需求的市場規模
  • 目標產品概況
  • 屬性和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵KOL洞察對領先新興治療方法的見解
  • 意識
  • 預期用途/處理線
  • 對主要未滿足需求的滿意度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Bristol-Myers Squibb
  • K36 Therapeutics, Inc.
  • Janux Therapeutics
  • Janssen Pharmaceutical
  • Celgene
  • AstraZeneca
  • POINT Biopharma
  • Amgen
  • TechnoGenesys, Inc.
  • Pfizer
  • Merck Sharp &Dohme LLC
  • Daiichi Sankyo
  • Aragon Pharmaceuticals, Inc.
  • AbbVie
  • BioNTech SE
  • Hoffmann-La Roche
  • Fusion Pharmaceuticals Inc.
  • Syncromune, Inc.
  • Astellas Pharma Global Development, Inc.
  • Arsenal Biosciences, Inc.
  • Atridia Pty Ltd.
  • Shanghai AbelZeta Ltd.
  • Regeneron Pharmaceuticals
  • Bayer
  • Novartis Pharmaceuticals
  • Tasly Pharmaceutical Group Co., Ltd
  • Blue Earth Therapeutics Ltd
  • Inmune Bio, Inc.
  • Celcuity Inc
  • Pathos AI, Inc.
  • IntoCell, Inc
  • Orano Med LLC
  • Nuvation Bio Inc.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興治療方法—概述和KOL洞察

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業性屬性
  • 產品定位

第4章：一級市場調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興治療方法
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

  • 新興治療方法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

簡介目錄

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy and TPP Insights

Thelansis's "Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview

Metastatic Castration-Resistant Prostate Cancer (mCRPC) represents an advanced and aggressive stage of prostate cancer characterized by disease progression despite castrate levels of testosterone achieved through androgen deprivation therapy. The condition is driven by persistent androgen receptor signaling and alternative resistance mechanisms, enabling continued tumor growth and metastatic spread.

Clinically, mCRPC predominantly metastasizes to bone and lymph nodes, leading to significant complications such as bone pain, fractures, spinal cord compression, and systemic symptoms including fatigue and functional decline. These manifestations substantially impact patient quality of life and contribute to high morbidity.

The current treatment landscape is multifaceted, incorporating next-generation androgen receptor pathway inhibitors, chemotherapy, radiopharmaceuticals, and supportive care. While these therapies have improved overall survival, treatment resistance and disease progression remain inevitable for most patients, highlighting the limitations of existing options. Consequently, mCRPC remains a major focus of oncology innovation, with ongoing development of targeted therapies, immunotherapies, radioligand therapies, and combination strategies aimed at improving durability of response and personalizing treatment approaches.

Key Highlights

  • In Italy, the diagnosed mCRPC patient pool is projected to increase from 37.5K in 2025 to 39.4K by 2035, indicating modest growth (0.5% CAGR) driven by aging population and improved survival.
  • Disease progression and therapeutic resistance remain key challenges, with most patients eventually exhausting available treatment options.
  • Increasing focus on precision oncology, radioligand therapies, and combination treatment strategies is expected to significantly evolve the future treatment landscape.

Market Overview

  • The Germany mCRPC market is projected to grow from $342M in 2025 to $538M by 2035, reflecting steady growth driven by continued adoption of novel oncology therapies.
  • Market expansion is supported by:
  • Uptake of next-generation androgen receptor inhibitors and radiopharmaceuticals
  • Increasing use of combination and sequential treatment strategies
  • Despite relatively modest patient growth (0.5% CAGR), market growth is driven by high-value therapies and extended treatment duration.
  • Future growth will depend on the successful integration of precision medicine approaches and novel modalities that improve survival outcomes and delay resistance.

Insights driven by surveys with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Bristol-Myers Squibb
  • K36 Therapeutics, Inc.
  • Janux Therapeutics
  • Janssen Pharmaceutical
  • Celgene
  • AstraZeneca
  • POINT Biopharma
  • Amgen
  • TechnoGenesys, Inc.
  • Pfizer
  • Merck Sharp & Dohme LLC
  • Daiichi Sankyo
  • Aragon Pharmaceuticals, Inc.
  • AbbVie
  • BioNTech SE
  • Hoffmann-La Roche
  • Fusion Pharmaceuticals Inc.
  • Syncromune, Inc.
  • Astellas Pharma Global Development, Inc.
  • Arsenal Biosciences, Inc.
  • Atridia Pty Ltd.
  • Shanghai AbelZeta Ltd.
  • Regeneron Pharmaceuticals
  • Bayer
  • Novartis Pharmaceuticals
  • Tasly Pharmaceutical Group Co., Ltd
  • Blue Earth Therapeutics Ltd
  • Inmune Bio, Inc.
  • Celcuity Inc
  • Pathos AI, Inc.
  • IntoCell, Inc
  • Orano Med LLC
  • Nuvation Bio Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)